FDA's Thinking On New Psychiatric Endpoints: What Does Brintellix CRL Portend For Nuplazid?
FDA deviated from its advisory committee's recommendation on the first cognitive function claim for an antidepressant when it issued a complete response letter for Brintellix. The decision could signal trouble for Acadia's Nuplazid for Parkinson's psychosis, which also relies on a new psychiatric endpoint.
You may also be interested in...
Alkermes revealed successful completion of its third Phase III trial for the depression drug ALKS 5461 as well as a risky plan to seek FDA approval based on two negative and one positive late-stage study.
Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.
Pink Sheet analysis finds that evidence from early-stage trials supports most BTD requests, but about three in 10 designations are granted on the basis of pivotal-stage data.